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ABSTRACT
Objective: To examine the experiences of patients,
health professionals and screeners; their interactions
with and understandings of diabetic retinopathy
screening (DRS); and how these influence uptake.
Design: Purposive, qualitative design using
multiperspectival, semistructured interviews and
thematic analysis.
Setting: Three UK Screening Programme regions with
different service-delivery modes, minority ethnic and
deprivation levels across rural, urban and inner-city
areas, in general practitioner practices and patients’
homes.
Participants: 62 including 38 patients (22 regular-
screening attenders, 16 non-regular attenders) and
24 professionals (15 primary care professionals and
9 screeners).
Results: Antecedents to attendance included
knowledge about diabetic retinopathy and screening;
antecedents to non-attendance included
psychological, pragmatic and social factors.
Confusion between photographs taken at routine eye
tests and DRS photographs was identified. The
differing regional invitation methods and screening
locations were discussed, with convenience and
transport safety being over-riding considerations for
patients. Some patients mentioned significant pain
and visual disturbance from mydriasis drops as a
deterrent to attendance.
Conclusions: In this, the first study to consider
multiperspectival experiential accounts, we identified
that proactive coordination of care involving patients,
primary care and screening programmes, prior to,
during and after screening is required. Multiple
factors, prior to, during and after screening, are
involved in the attendance and non-attendance for
DRS. Further research is needed to establish whether
patient self-management educational interventions
and the pharmacological reformulation of shorter
acting mydriasis drops, may improve uptake of DRS.
This might, in turn, reduce preventable vision loss
and its associated costs to individuals and their
families, and to health and social care providers,
reducing current inequalities.
INTRODUCTION
Visual impairment is a signiﬁcant worldwide
health problem.1 2 Approximately 314
million people globally are visually impaired,
with over 80% of this impairment being pre-
ventable or treatable.1 3 Diabetic retinopathy
is a major cause of preventable vision loss in
people with type 1 and type 2 diabetes in
Europe, Africa, Asia and Australia4–13 and,
until recently,14 has been the leading cause
of preventable vision loss in European
working-age populations.4 8 10–12 The propor-
tion of vision loss caused by diabetic retinop-
athy is increasing globally.13 In addition to
treatment costs, lost productivity and quality
of life for patients with diabetic retinopathy
contribute to personal and socioeconomic
burdens.15
Strengths and limitations of this study
▪ Our purposive sampling strategy recruited
several strata of professional groups in general
practitioner and optometry practices and screen-
ing programmes, and in regular as well as less-
regular attending patients. Additionally, we
recruited from diverse city, town and rural loca-
tions, and included programmes with different
regional invitation and delivery modes.
▪ Not every permutation between location type,
deprivation and delivery-mode was studied. We
did not recruit any practice that delivers screen-
ing in a mobile unit or hospital outpatients
department so did not interview Hospital Eye
Service staff, and only two practices provided
optometrist screening.
▪ The qualitative findings from our purposive
sample are not intended to be representative, but
highlight important insights into barriers and
enablers to screening attendance that will inform
further research.
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Adequate diabetes control, regular screening and
timely laser treatment can prevent visual impairment.1 15
In England, routine diabetes care and diabetic retinop-
athy screening (DRS) are principally managed in primary
care, while treatment for retinopathy takes place in sec-
ondary care. Issues surrounding diabetic retinopathy,
therefore, have practice implications for medical and
health professionals working in both settings. The UK
Government’s measurement of preventable vision loss
from April 2013 recognises this top public health priority.
The English NHS Diabetic Eye Screening Programme
offers cost-effective annual screening to people with dia-
betes (types 1 and 2) over 12 years16 where 80% uptake is
achieved. Screening uptake is assessed at the general
practice level. Screening modes differ regionally, taking
place either in general practitioner (GP) surgeries, hospi-
tals or optometry practices (see ﬁgure 1). Screening typic-
ally takes 30 minutes. Patients’ pupils are dilated with
drops, affecting their vision for 4–6 h. Digital photo-
graphs are taken and the images examined by regional
NHS retinal grading teams, who identify any pathology.
Results are communicated to the patient and the GP.
Patients with retinopathy requiring monitoring or treat-
ment are referred to the Hospital Eye Service.
However, approximately 20% of people invited for DRS
do not attend,17 with those from minority ethnic back-
grounds and people living in deprived areas less likely to
attend and more likely to have worse retinopathy.18–20
Inequalities in access to DRS in Englandi have led to calls
for further research,19 including qualitatively.21
Yet, deprivation alone does not explain all the uptake
variability between GP practices and regions. For
example, misunderstandings about the importance of
diabetes and personal risk factors, and patients’ lack of
awareness, psychological factors or practical obstacles,
can represent major barriers to attending screening.22
However, as attendance rates vary greatly between neigh-
bouring practices, for example, from 55% to 95% in
Gloucestershire,23 research focusing beyond deprivation,
risk factors or barriers is required. Little is known about
how patients’ and professionals’ perceptions and experi-
ences of DRS may inﬂuence attendance. This paper,
therefore, focuses on the experiences around DRS that
may affect uptake from the accounts of people with dia-
betes and GP practice and screening staff.
METHODS
NRES Committee South West—Cornwall and Plymouth
gave ethical permission (10/H0203/79) and all partici-
pants gave their informed consent. This work was sup-
ported by the National Institute of Health Research,
Research for Patient Beneﬁt grant PB-PG-1208–18043
and sponsored by Gloucestershire Hospitals NHS
Foundation Trust.
Design of the research: This multiperspectival,24 cross-
sectional qualitative interview study used purposively
sampled GP practices in four UK Primary Care Trusts
across three regions, based on Indices of Multiple
Deprivation, practice type, screening mode and screen-
ing uptake (see table 1).
Practice recruitment: Central England Primary Care
Research Network and South West Diabetes Network
provided research nurse assistance with GP practice
recruitment.
Twelve GP practices were approached; two declined
(existing research commitments); one withdrew prior to
the start of participant recruitment (staff changes).
Table 1 details the characteristics of nine participating
GP practices. The Central Local Research Network paid
service support costs of £599.27 to the participating GP
practices.
Participant recruitment
Professionals: We purposively recruited 24 primary care and
screening professionals with patient contact in differing
roles around DRS, to ensure a broad spectrum of views
and experiences. Patients: Within each practice, patients
were purposively sampled based on their screening attend-
ance history, to consider differences in attitudes and
experiences. ‘Regular attenders’ had attended all three of
their most recent DRS appointments; ‘Non-regular atten-
ders’ had attended none or one of their three most recent
DRS appointments. Practice staff telephoned potential
participants and sent information packs.
Interviews: Semistructured interviews were conducted
either face to face at the GP/optometry practice, in
patients’ homes, or by telephone, at participants’ discre-
tion. Multiperspectival interviews allowed us to under-
stand the dynamics between patients, professionals and
the Screening Programme, and to explore similarities
and differences in their perceptions to highlight poten-
tially differing needs and suggestions for improving ser-
vices. Questions were aimed to capture the descriptions
of participants’ experiences before, during and after the
screening appointment, from professionals’ and
patients’ perspectives; identifying factors they believed
inﬂuence screening attendance (see online supplemen-
tary appendices 1 and 2). All interviews were audio-
recorded and transcribed verbatim, prior to analysis. No
additional data are available for data-sharing.
Analysis: Data were managed using QSR NVivo10 soft-
wareii to code and review themes. AEH undertook itera-
tive, thematic analysis, using constant comparison
within and across all transcripts. Looking for overarch-
ing themes and relations between them, AEH identi-
ﬁed speciﬁc major and minor categories within the
themes that might interact to inﬂuence screening
attendance rates. AEH and AL met to discuss these
themes and agreed on the deﬁnitions of the emerging
ihttp://www.screening.nhs.uk/news.php?id=12156. iiwww.qsrinternational.com/.
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Figure 1 Diabetic eye screening
programme delivery modes
(GP, general practitioner).
Table 1 Practice characteristics
Practice number
Screening
programme area IMD Practice type
Screening
delivery mode
Uptake
rate (%)
Practice 1 Region 1 Deprived Urban city GP practice 96
Practice 2 Region 1 Below average Rural town GP practice 88
Practice 3 Region 2 Deprived Rural town GP practice 85
Practice 4 Region 2 Above average Rural town GP practice 75
Practice 5 Region 1 Deprived Rural town GP practice 73
Practice 6 Region 1 Below average Urban city GP practice 72
Practice 7 Region 2 Least deprived Rural town GP practice 71
Practice 8 Region 3 Most deprived Inner city High street optometrist 68
Practice 9 Region 3 Most deprived Inner city High street optometrist 57
GP, general practitioner; IMP, index of multiple deprivation.
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codes. Findings were discussed with all authors until a
consensus was reached about the interpretation of key
themes. Finally, AEH checked these interpretations
with the existing data.
RESULTS
Characteristics of the sample: Sixty-two participants (33
female) were interviewed between September 2011 and
July 2012, by AEH, AL and JS (see table 2). Of the 38
patients, 4 have type 1 diabetes (mean age 49); 34 have
type 2 (mean age 60); 22 were regular retinopathy-
screening attenders, 16 were non-regular attenders
(deﬁned above). Of the 24 professionals (mean age 50),
8 are primary healthcare professionals, 7 are administra-
tive practice staff and 9 are DRS programme screeners.
No theme was unique, either to the regular attenders
or non-regular attenders, which highlights the complex
nature of why people do or do not attend appointments.
Understandings of diabetic retinopathy and screening
The GP practice staff, screeners and patients identiﬁed
several antecedents to attendance and non-attendance
at screening. Regular and non-regular attending patient
participants both acknowledged the importance of DRS.
Yet, confusion around screening was clearly identiﬁed in
all participant groups, as was the need to overcome this.
Understandings of diabetic retinopathy
Some (but not all—see later subthemes) people with
diabetes understood the causal factors and the potential
consequences of diabetic retinopathy; protecting their
eyes appeared to be a priority for some. Interestingly, a
non-regular attender with vicarious experience of sight
loss identiﬁed herself to the researcher as a regular
attender. Others found the process reassuring.
It’s the smallest vessels that go ﬁrst, and it’s one of the
quickest ways of seeing the effects is in the eyes. But...the
body is so tolerant, you don’t recognise that the vision is
going until it’s too late. Patient 8 (Region 2, Regular)iii
I: So what is it that encourages you to come [to screen-
ing] then?
P: My brother-in-law he was a very bad diabetic...He actu-
ally died from it. He went blind ﬁrst. Patient 13 (Region
3, Non-regular)
I like the fact that you instantly see and can get a decent
steer on if there is anything negative; it’s complete peace of
mind – well my results anyway. Patient 3 (Region 2, Regular)
Psychological, pragmatic and social influences on
non-attendance
In response to being asked why people might not attend
DRS, professionals and patients both acknowledged that
denial of having diabetes could contribute. One patient
missed screening appointments because she disliked the
proximity of the screener. Pragmatic reasons raised by
the non-regular attenders for non-attendance included
work commitments and postoperative recuperation.
Some people just… have their head in the… like the
ostrich, they don’t have diabetes or they’re not taking
any notice of it and they will just… yes, not come. Some
because they think they can’t have the time off work, you
know? Screening Programme 1 (Region 1)
It’s just the thought of somebody coming close to my eye.
Patient 15 (Region 3, Non-regular)
I missed once, because I had an abscess in an awkward
place, and I had to have an operation. But the following
year I made sure. Patient 5 (Region 3, Non-regular)
Another non-regular attender who identiﬁed herself
as a regular attender had attempted to access DRS via
her GP practice, but was refused because she was in a
temporary accommodation waiting to be rehoused. This
highlights the complex social context in which people
with diabetes experience screening:
Int: So you didn’t always come?
Pt: Well, with being homeless for 8 weeks...But they [GP
practice] didn’t want to know. ‘Oh you’re not in our
area.’ I’m in nobody’s area because we were in a bed and
breakfast; they were my last doctors. Patient 10 (Region
1, Non-regular)
Table 2 Programme and participant characteristics
Screening programme
Regional descriptor
Region 1
Urban city/rural town
Region 2
Rural town
Region 3
Inner city Total
Number of practices 4 3 2 9
Patients (non-regular attenders) 14 (5) 8 (1) 16 (10) 38 (16)
Medical practice staff (GPs, optometrist, HCAs, nurses) 2 3 3 8
Administrative practice staff (receptionists, managers) 4 2 1 7
Screeners 4 4 1 9
Total participants 24 17 18 62
GP, general practitioner; HCA, health care assistant.
iiiR=region from table 1; regular attender/non-regular attender (as
deﬁned above).
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Understandings of DRS versus routine eye test
Some patients’ perceptions of screening attendance
were confused by high street optometry practices rou-
tinely taking photographs during a general annual eye
check. Patients confused this with DRS even in areas
where high street optometry practices did not conduct
DRS, confounding attendance:
I’m with [high street optometry chain] so I’ve always,
always had my eyes screened...So when I was diagnosed
and I told the optician she said, well we can do that here
for an extra £10 and we will just email the surgery. So I
thought ﬁne, that’s ﬁne. So I just bypass it completely...
Patient 4 (Region 2, Non-regular)
A lot of people turn up and say, ‘well I had my optician’s
test’ and you...explain to them that although it’s a great
thing to have and they need to have it, we still need to
do our tests because it’s more accurate, and we’re search-
ing speciﬁcally for the diabetic retinopathy. Screening
Programme 1 (Region 1)
Perceived responsibility for patients’ understandings of DRS
Professionals and patients identiﬁed the need to
improve patients’ understandings about DRS and sight-
threatening retinopathy. For example, one GP accepted
that low uptake reﬂected a failure to deliver the right
message. However, more direct input from the health
professional team was suggested by one patient who had
not understood the screening information, and subse-
quently developed retinopathy. One screener considered
that the lack of media attention to DRS could contribute
to low attendance.
Why haven’t they taken that onus of control, what is it
that they don’t believe about their diabetes? Where have
we gone wrong in trying to get that message across?...the
words “Diabetic Retinopathy Screening”, what does that
mean to them? Health Professional 1 (Region 3)
As soon as I had diabetes diagnosed somebody should
have explained to me more fully what the implications
are. Because it’s alright them giving you a leaﬂet and
sending you home...but even though you read it, there’s
this kind of silly thing, ‘oh it won’t happen to me’, atti-
tude. Patient 15 (Region 3, Non-regular)
I don’t think screening is something that’s pushed as much
as other screening. I mean retinal screening is…I’d say it’s
important...but things like breast cancer, there’s a lot more
press about it. Screening Programme 2 (Region 1)
Accessing DRS
This theme highlights participants’ varying experiences
and perceptions around making the appointment, getting
there—and back, which patients had difﬁculties with.
Pre-booked versus self-booked appointments
Invitation methods vary with regions (see ﬁgure 1), with
professionals and patients identifying issues around both
modalities that could affect uptake. Patients need to be
proactive, either to make their appointment or change
an inconvenient pre-booked appointment (depending
on where they live). All participant groups identiﬁed
that patients could forget to do either, while this
appeared particularly problematic for working patients.
But it does rely on the patient being proactive. You get
an appointment, alphabetical order, totally inconvenient,
impractical time, what do you do, do you do nothing and
forget it or do you ring up and change it? And if you
don’t ring up and change it then nothing happens,
you’re just a DNA statistic aren’t you really. Screening
Programme 3 (Region 1)
Int: So you get a letter with the appointment
pre-booked?
Pt: Yes. And then if you can’t make it you change it.
Int: You wouldn’t prefer to be able to ring yourself and
make an appointment?
Pt: No, because I think you’d tend to forget wouldn’t
you, and I think most people would. Patient 3 (Region 1,
Regular)
Patients are used to receiving pre-booked appoint-
ments for other diabetes clinics (eg, Practice Nurse
appointments to be weighed and have their feet
checked). Professionals felt that expecting patients to
make their own DRS appointment downgraded its per-
ceived importance to patients, or was not patients’
responsibility. This was exacerbated by the perceived
rigidity of the appointment-booking system in another
region.
I think if it’s left to the patient a lot of the time they
don’t think, because they have to do it, it’s not that
important. Health Professional 4 (Region 3)
Why should a patient… if it was a blood test… would the
GP just say, go and sort it out yourself, and the patient is
just registering himself at the hospital, getting a blood
test and making sure the GP gets it? That’s ridiculous.
Screening Programme 1 (Region 3)
I get a letter saying I need to make a phone call between
speciﬁc times on speciﬁc dates and they give you a block
of dates...to make the appointment in advance...a good
6 weeks. Patient 5 (Region 2, Regular)
Patients in the area delivering DRS through high
street optometry reported an absence of available
appointments:
Well before the appointment I phoned and they said no,
they’d got no appointments for the next three months...
The following year again the same thing, I phoned when
I had the letter, they said three months’ waiting. Patient 5
(Region 3, Non-regular)
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Integrating diabetes appointments
Patients in different regions suggested that DRS would
be better if integrated with their other diabetes care as
this would reduce the inconvenience of attending
numerous appointments:
Probably would be better if it was done the same time as
you have a normal diabetic appointment...I mean I’ve had
to come up here on the Tuesday because they wanted to
check my weight and then I think it was the Wednesday to
have my eyes done and I’m thinking, do I need to come
up twice [laughs]. Patient 8 (Region 1, Regular)
Transport
Getting to and from screening appointments was
important pragmatically for many patients, who had to
overcome a range of issues. One health professional
recognised that transport issues and the proximity of
screening to patients’ homes potentially affected uptake,
apparently understanding patients’ reticence to travel—
although without the insight into the difﬁculties that
some patients experienced:
Most patients around here like to go to things that are
within walking distance or within a bus stop, if that. So
transport is an issue. …they know the surgery, ‘oh the
surgery is next door, I know the girls there, they’re always
there’...So maybe I need to have the retinopathy screen-
ing done at the surgery and they’d all come [laughs].
Health Professional 1 (Region 3)
Patients are advised not to drive to/from DRS appoint-
ments, because the mydriasis drops cause blurred vision
and photosensitivity (detailed later). The pragmatic
repercussions of this were especially noteworthy for
working age people. However, alternative travel arrange-
ments also emerged as impractical because blurred
vision caused an inability to navigate efﬁciently.
I am tied to either making them [screening appoint-
ments] in the afternoon and then getting home, so I
have to work out how to get into work in the morning
that doesn’t involve driving, or I have to be there [GP
practice] earlier, say lunch time or something, I have to
take a half day. Patient 5 (Region 2, Regular)
Because of the drops, it makes it difﬁcult for the people’s
journey...it’s like a cobweb on top of your eyes and… No
I can’t see at all...We have to have the eye drops so it’s
very hard to either walk it back …I felt I was blinded tem-
porarily and got into a taxi and then got out of the car
somehow. I had to cross the road and I was just looking
like that [stares blankly] because I was waiting for the
taxi and I had to do like that [waves arms]… Patient 5
(Region 3, Non-regular)
Screening experiences
This theme incorporates experiential accounts of the
actual screening appointments of patients, including
negative experiences of lengthy appointments in high
street optometry practices, compared with efﬁcient GP
practice appointments. Mydriasis drops caused severe
side-effects and subsequent adverse effects for some
patients, who discussed strategies to overcome them.
Appointment length
In one region, appointments lasting for several hours at
optometry practices were potentially a deterrent. One
patient recognised that lengthy food abstinence was par-
ticularly inappropriate for diabetes patients, while
another overcame the problem by changing practice.
Yes, the ﬁrst time I went to...the local optician...I was
there for 5 hours, from 10 o’clock in the morning, and
by the time I got out of the door it was 3 o’clock....And
by then I can remember I was so hungry and I thought,
‘well how does that help a diabetic person?’ Patient 5
(Region 3, Non-regular)
I had my optician before and he was quite slow, the
drops used to sting and he used to take a long time. I
had to be there for about two or three hours. But my
present optician is good. Patient 1 (Region 3, Regular)
However, in sharp contrast, where screening was deliv-
ered in GP practices, satisfaction with short, efﬁcient
appointments had been reported.
They’re quite good actually, see you straight away, well
within, you know...about ten minutes of your appoint-
ment... Patient 8 (Region 1, Regular)
It doesn’t take half an hour I suppose at the outside.
Patient 1 (Region 2, Regular)
Side effects of drops
Mydriasis drops dilate the pupil, allowing more light
into the eye and a clearer retinal photograph to be
taken. However, in another important ﬁnding, regular
and non-regular patients experienced severe pain,
blurred vision and debilitating photosensitivity for
several hours. Interestingly, none of the health profes-
sionals except the optometrist raised this, suggesting
they were unaware of this issue.
AEH: you come and they put the drops in do they?
P: Oh yes. They were like acid burning my eyes this
time...It really hurt this time. Patient 1 (Region 1,
Non-regular)
Everything else is ﬁne, it’s just the drops, they sting like
hell. Patient 3 (Region 1, Regular)
And I hate that because it affects my eyes for so long and
I can’t… put my lenses back in straight away so someone
is with me because I can’t see... Patient 4 (Region 2,
Non-regular)
I would advise anybody to bring sunglasses even if it’s not
particularly bright...if I had them I’d wear dark goggles
6 Hipwell AE, et al. BMJ Open 2014;4:e005498. doi:10.1136/bmjopen-2014-005498
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so that they’re closed in. Like welders goggles [laughs].
Actually no like swimming goggles but darker, to keep all
the light out from the sides now, because it’s painful.
Patient 5 (Region 2, Regular)
If someone tomorrow has drops put in because of the
service and they just happen to have a reaction to the
drops, and they lose their eyesight...So then who are they
going to sue? …if push comes to shove we’re the ones
[optometrists] who are going to get sued. Screening
Programme 1 (Region 3)
DISCUSSION
Results in context
For some patients and practices, the DRS programme
worked well and we conﬁrm previous ﬁndings that a
convenient screening location near home was beneﬁ-
cial24 and that preserving vision was prioritised among
patients with diabetes.25 We also conﬁrm previous
studies ﬁnding that for others, misunderstandings about
the importance of diabetes and personal risk,22 26 lack
of DRS awareness, psychological factors, practical obsta-
cles22 and the deterrent side effects of mydriasis27 repre-
sented potential attendance barriers.
No clear distinction between regular and non-regular
DRS attenders was identiﬁed. In an important new
ﬁnding, we uncovered confusion between routine retinal
photography at optometry practices during eye examina-
tions and DRS. While optometry photography may rep-
resent an important safeguard for non-attenders, it
could impair more comprehensive coverage. We
observed differences between patients screened at GP
versus optometrist practices, identifying that ease of
making an appointment, including its time, navigating
home after the mydriasis drops, etc, appeared less prob-
lematic at GP practices. Furthermore, making patients
responsible for arranging appointments in some
regions, combined with encountering delays, could
undermine the perceived importance of DRS. We have
identiﬁed patients’ misperceptions about their attend-
ance regularity.
Strengths and limitations of the study
The strengths of this study include the purposive sam-
pling strategy across several strata of professional groups
in GP and optometry practices and screening pro-
grammes, and recruiting regular and less regular attend-
ing patients. Additionally, we recruited from diverse city,
town and rural locations, and included programmes
with different regional invitation and delivery modes.
However, not every permutation between location type,
deprivation and delivery mode was studied. We did not
recruit any practice that delivers screening in a mobile
unit or hospital outpatients department; so did not inter-
view Hospital Eye Service staff, and only two practices
provided optometrist screening. The qualitative ﬁndings
from our purposive sample are not intended to be rep-
resentative but to highlight sociocultural meanings of
health and illness experiences, not simply their fre-
quency, and identify important insights into barriers and
enablers to screening attendance among our partici-
pants that will inform further research.
Implications for clinicians and policy makers
While some patients understood retinopathy and its
causation, others lacked information and understanding
about DRS. This calls for proactive personal clinical risk
communication28 29 and attendance information to
ensure care coordination between patients, primary
care, screeners and screening programmes. The current
guidance to bring sunglasses could be strengthened in
the patient information. Some patients had confused
retinal photography at optometry practices with DRS.
Professional optometry bodies could ensure clarity
among members, and optometrists should highlight the
difference to their patients. Consideration may be appro-
priate around the responsibility that the NHS has when
discharging visually impaired patients into the commu-
nity. In Scotland, a 3-stage screening procedure is used;
stage 1 is one ﬁeld non-mydriatic photography, stage 2 is
dilation, stage 3 is slit-lamp biomicroscopy on those with
poor quality mydriatic images who required dilation in
stage 2. The Scottish Screening Programme dilate
approximately 34% of their population. The English
Screening Programme developed following the evidence
provided for 2-ﬁeld digital photography by the Scanlon
et al30 study, which recommended dilated two-ﬁeld
imaging. Culturally sensitive improvements21 should
build on the recent introduction of patient information
leaﬂets in several languages.iv
Several providers now deliver DRS in the UK, and since
this research was conducted, Public Health England is
responsible for overseeing delivery and the ﬁnancial incen-
tive for GPs to record screening uptake has been removed.
These changes may affect future practice involvement and
patient uptake; this fast-moving ﬁeld requires monitoring
closely. Building on the successful central appointments
system and practice factors that affect DRS attendance31
may prove useful. The national implementation of the
new screening pathway should ensure consistent delivery
throughout the country, improving the quality of services
and reducing variability.32
Future research
Much more work is needed is this ﬁeld. A similar exer-
cise should be undertaken among a representative
national sample of programmes, taking into account
demographic variables that we found to be relevant
(ethnicity, delivery mode, deprivation etc). More work is
needed to determine the prevalence of the views of
patients and clinicians on the appropriate design and
delivery of DRS services to maximise attendance; hos-
pital staff may provide insightful alternatives for service
ivhttp://diabeticeye.screening.nhs.uk/languages.
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improvement. The pharmacological reformulation of
shorter acting mydriasis drops to minimise side effects
may reduce disruption to patients and potentially
beneﬁt uptake rates, although we acknowledge that this
would not address the pain participants had reported.
The extent of confusion about optometry photography
needs urgent assessment.
CONCLUSIONS
This study uses the experiences of the DRS staff and
patients to start unpicking factors affecting uptake. The
factors identiﬁed include differing regional invitation
methods and screening locations, convenience, trans-
port safety and short appointment times; some patients
experienced signiﬁcant side effects from mydriasis
drops. The successful implementation of the new care
pathway should address these factors, which may
improve DRS attendance. Used as an international
model, this could, in turn, contribute to reducing pre-
ventable vision loss and inequalities globally, and its asso-
ciated costs to individuals and their families, as well as to
primary, secondary and social care providers.
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